Quinoxaline chemistry. Part 12. 3-Carboxy-2[phenoxyl-6(7)substituted quinoxalines and N-[4-(6(7) substituted-3-carboxyquinoxalin- 2-yl)hydroxy]-benzoylglutamates. Synthesis and evaluation of in vitro anticancer activity

Farmaco

Volumn 53, Issue 8-9, 1998, Pages 594-601

  Vitale, Gabriella ^a   Corona, Paola ^a   Loriga, Mario ^a   Paglietti, Giuseppe ^a  

^a UNIVERSITY OF SASSARI   (Italy)

Author keywords

Anticancer agents; Phenoxyquinoxalines; Quinoxaline derivatives

Indexed keywords

GLUTAMIC ACID DERIVATIVE; QUINOXALINE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DRUG SCREENING; DRUG SYNTHESIS; HUMAN; HUMAN CELL;

ANTINEOPLASTIC AGENTS; CELL DIVISION; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; QUINOXALINES; SPECTRUM ANALYSIS; TUMOR CELLS, CULTURED;

EID: 0032464876     PISSN: 0014827X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-827X(98)00075-5     Document Type: Article

References (6)

1. M. Loriga, M. Fiore, P. Sanna, G. Paglietti, Quinoxaline chemistry. Part 4: 2-(R)-anilinoquinoxalines as non-classic antifolate agents. Synthesis, structure elucidation and evaluation of in vitro anticancer activity, Farmaco 50 (1997) 289-301.
2. M. Loriga, S. Piras, P. Sanna, G. Paglietti, Quinoxaline chemistry. Part 7: 2-[Aminobenzoates] and 2-[aminobenzoylglutamate] quinoxalines as antifolate agents. Synthesis and evaluation of in vitro anticancer, anti HIV and antifungal activity, Farmaco 52 (1997) 157-166.
3. P. Corona, G. Vitale, M. Loriga, G. Paglietti, Quinoxaline chemistry. Part 11 - 3-Phenyl-2[phenoxy- and phenoxymethyl]6(7) or 6,8-substituted quinoxalines and N[4-(6(7)substituted or 6,8-disubstituted-3-phenylquinoxalin-2-yl)hydroxy or hydroxymethyl]benzoylglutamates. Synthesis and evaluation of in vitro anticancer activity and enzymatic inhibitory activity against dihydrofolate reductase (DHFR) and thymidylate synthase (TS), Farmaco 53 (1998) 480-493.
4. E.I. Fairburn, B.I. Magerlein, L. Stubberfield, E. Stapert, D.I. Weisblat, Oxygen analogues of pteroic acid, J. Am. Chem. Soc. 76 (1954) 676-678.
5. M.R. Boyd, Status of the NCI preclinical antitumor drug discovery screen, Princ. Pract. Oncol. 3 (10) (1989) 1-12.
6. O.V. Weislow, R. Kiser, D. Fine, J. Bader, R.H. Shoemaker, M.R. Boyd, New Soluble-Formazan assay for HIV-1 cytophathic effect: application to high-flux screening of synthetic and natural products for AIDS antiviral activity, J. Natl. Cancer Inst. 81 (1989) 577-586.